Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reteplase - Chiesi Farmaceutici

Next Previous
Drug Profile

Reteplase - Chiesi Farmaceutici

Alternative Names: CUSA-081

Latest Information Update: 23 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Catheter thrombosis

Most Recent Events

  • 10 Jul 2023 Chiesi Farmaceutici terminates the phase III READY 1 trial for Catheter thrombosis in Argentina, Belgium, Poland, Romania, Spain, USA and Czech Republic (Intraluminal), due to ongoing recruitment challenges and the decision was not based on any reported changes in the safety profile or any concerns with the anticipated efficacy profile (NCT03594175) (EudraCT2019-002124-32)
  • 15 Apr 2022 Chiesi Farmaceutici withdraws phase III trial in Catheter thrombosis in Bulgaria, Hungary and in the US (NCT03992443)
  • 22 Mar 2022 Reteplase is still in phase III trials for Catheter thrombosis in Argentina, Belgium, Poland, Romania, Spain, USA and Czech Republic (Intraluminal) (NCT03594175)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top